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Aim: Factor V Leiden (R506Q) mutation is the most commonly observed inherited genetic 
abnormality related to vein thrombosis. Lebanon has one of the highest frequencies of this 
mutation in the world with a prevalence of 14.4% in the general population. The aim of this 
study is to define risk factors including inherited genetic abnormalities among Lebanese patients 
with lower extremity deep vein thrombosis. We report the clinical outcome of patients with 
thrombophilia.
Methods: From January 1998 to January 2008, 162 patients (61 males and 101 females) were 
diagnosed with lower extremity deep vein thrombosis. Mean age was 61 years (range: 21 to 
95 years).
Results: The most frequent risk factors for vein thrombosis were surgery, advanced age, 
obesity, and cancer. Twenty-five patients had thrombophilia, 16 patients had factor V Leiden 
(R506Q) mutation, and seven patients had MTHFR C677T mutation. Ninety-two percent of 
patients screened for thrombophilia were positive. Screening was requested in young patients 
(16), patients with recurrent (11), spontaneous (8), and extensive (5) venous thrombosis, familial 
history (5), pregnancy (4), estroprogestative treatment (3), and air travel (1). Nine patients had 
one, 11 patients had two, and five had three of these conditions. Follow-up (6 to 120 months) of 
these 25 patients treated with antivitamin K did not reveal recurrences or complications related 
to venous thromboembolism.
Conclusion: Factor V Leiden mutation followed by MTHFR mutation are the most commonly 
observed genetic abnormalities in these series. Defining risk factors and screening for 
thrombophilia when indicated reduce recurrence rate and complications. Recommendations 
for thrombophilia screening will be proposed.
Keywords: venous thrombosis, risk factors, genetics, factor V Leiden, prothrombin G20210A, 
MTHFR C677T
Introduction
Lower extremity deep venous thrombosis (DVT) remains a common and serious 
medical condition manifesting in patients with recognized or unrecognized risk 
factors and complicates the outcome of critically ill patients and the postoperative 
recovery of surgical patients. More than one million cases of DVT are diagnosed 
in the United States annually, resulting in approximately 50 to 20,000 deaths 
due to pulmonary embolism (PE).1,2 The pathogenesis of DVT is multifactorial 
and involves environmental, acquired, and genetic factors. In recent years, 
many authors have confirmed that thrombophilia, either acquired or genetic and 
defined as a predisposition to increased risk of venous and occasionally arterial Vascular Health and Risk Management 2009:5 628
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thromboembolism due to hematological abnormalities, was 
often responsible for the occurrence of lower extremity 
DVT.3–8 They recommended the detection of inherited 
genetic predisposing factors to thrombophilia in patients 
with spontaneous, unprovoked vein thrombosis and in 
patients with venous thrombosis associated with a family 
history of venous thromboembolism (VTE). Factor V 
Leiden (R506Q) mutation is the most commonly observed 
inherited genetic abnormality leading to thrombophilia and 
vein thrombosis. Lebanon has one of the highest frequencies 
of this mutation in the world with a prevalence of 14.4% 
of the general population.9
The aim of this study is to define risk factors, including 
genetic abnormalities, in a series of Lebanese patients 
with lower extremity DVT, to assess the contribution of 
thrombophilia to the constitution of venous thrombosis, to 
report clinical outcome of the patients with DVT associated 
with thrombophilia, and to propose recommendations for 
thrombophilia screening in patients with DVT.
Materials and methods
From January 1998 to January 2008, 162 patients (61 males, 
101 females) were diagnosed at Saint George Hospital, 
University Medical Center for lower extremity DVT by 
duplex scan examination. The mean age was 61 years 
(range: 21 to 95 years). One hundred nineteen (73%) were 
outpatients and 43 (27%) were hospitalized patients. Venous 
thrombosis was localized on the left side in 94 patients (58%), 
on the right side in 57 patients (35%), and on both sides in 
11 patients (7%). Venous thrombosis was observed at the 
iliofemoral level in 49 patients (30%), at the femoropopliteal 
level in 47 patients (29%), and at the calf level in 66 patients 
(41%). Nine patients had PE. Eight patients presented with 
DVT and PE and one patient had a delayed PE.
One hundred fifty-eight patients were treated with low 
molecular weight heparin and then antivitamin K. Four 
patients required inferior vena cava filter insertion for 
resistance to anticoagulation (one case of osteosarcoma) 
and for contraindication to anticoagulation (three cases of 
recent craniotomy, recent spine surgery, and recent major 
abdominal surgery).
Patients with specific conditions suggestive of throm-
bophilia were screened for genetic mutation abnormalities. 
Patients with DVT associated with thrombophilia were 
treated with antivitamin K: 11 short-term, 14 long-term or 
lifelong (target international normalized ratio [INR]: 2.5; 
range 2 to 3). These 25 patients were followed for a long 
period (mean: 50 months; range: 6 to 120 months) to study the 
incidence of venous thrombosis recurrence and the incidence 
of events related to VTE.
Results
The most common acquired predisposing risk factors 
for DVT observed in these series were advanced age 
(20%) and surgery (19%). Orthopedic surgery had the 
higher incidence of DVT (11%), followed by general 
surgery (4%), cardiac surgery (3%), neurosurgery (3%), 
gynecology (1%), and vascular surgery (1%). Eighteen 
percent of the patients were obese. Sixteen percent of the 
patients had malignancy with metastasis (5%) and direct 
venous compression (2%). The most commonly observed 
malignant tumors associated with venous thrombosis 
were cancer of the colon, breast, and pancreas. The 
other acquired risk factors were history of VTE (9%), 
immobilization (9%), heart failure (8%), estroprogestative 
treatment (7%), chronic obstructive pulmonary disease 
(7%), varicose veins (6%), pregnancy and postpartum 
(4%), fracture (2%), Crohn’s disease (2%), long-haul air 
travel (2%), paralysis (2%), family history of VTE (2%), 
trauma (2%), and cardiac catheterization (1%).
Twenty-five patients (15.4%) had thrombophilia 
(hypercoagulation). Twenty had one and five had two 
inherited genetic predisposing factors: antiphospholipid 
syndrome (1), heterozygote prothrombin G20210A mutation 
(1), heterozygote methylenetetrahydrofolate reductase 
(MTHFR) C677T mutation (7), factor V Leiden (R506Q) 
mutation (16; homozygote [1], heterozygote [15]) of 
whom five had associated protein C deficiency (1), 
protein S deficiency (1), MTHFR C677T heterozygote 
mutation (2), and prothrombin G20210A heterozygote 
mutation (1) (Table 1). Five patients had an increased 
Table 1 Patients with deep vein thrombosis of lower extremities 
and thrombophilia
Thrombophilia  Number  
of patients
Heterozygote prothrombin g20210A mutation 1
Heterozygote MTHFR c677Tc mutation 7
Antiphospholipid syndrome 1
Homozygote factor   V Leiden mutation 1
Heterozygote factor   V Leiden mutation 15
Protein C deficiency 1
Protein S deficiency 1
MTHFR mutation 2
Prothrombin mutation 1Vascular Health and Risk Management 2009:5 629
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homocystein plasmatic level which was isolated in two 
patients and associated with MTHFR mutation in three 
patients. Of the seven patients heterozygous for MTHFR 
C677 T mutation, two were heterozygous for factor V Leiden 
(R506Q) mutation and neither of these two patients showed 
an increased homocystein level.
Ninety-two percent of the patients tested for thrombo-
philia were positive. Screening was considered in young 
patients (16), recurrent thrombosis (11), spontaneous 
thrombosis (8), extensive thrombosis (5), family history of 
VTE (5), pregnancy (4), estroprogestative treatment (3), and 
long-haul air travel (1). Nine patients had one, 11 patients 
had two, and five patients had three of these conditions. 
Of the 25 patients screened for thrombophilia, 11 were 
treated with short-term antivitamin K and 14 were treated 
with long-term or lifelong antivitamin K. Follow-up of 
these patients during a mean period of 50 months (range: 
6 to 120 months) did not reveal any case of recurrence or 
complications related to VTE.
Discussion
Acquired risk factors for venous thrombosis of the lower 
extremities are well documented in the literature.8,10–15 The 
most frequently reported risk factors were surgery, cancer, 
trauma, and critical care conditions.16–18
The risk of venous thrombosis is high in cancer patients 
and in patients undergoing major surgery, essentially major 
orthopedic surgery. In major trauma, spinal cord trauma, 
and in critical care situations, this risk is extremely high and 
may reach 80%.16 The frequency of thrombophilia outside 
the setting of surgery, trauma, or cancer is approximately 
25%. Either alone, or associated with acquired risk factors, 
thrombophilia increases significantly the risk of venous 
thrombosis.
In the reported series, thrombophilia was detected in 
15.4% of the patients with DVT and in 92% of the patients 
with DVT associated with high risk conditions for hyperco-
agulation. It is considered as the fifth most frequent cause 
of DVT occurring after major acquired risk factors such as 
advanced age, surgery, obesity, and cancer.
Resistance to activated protein C caused by a mutation in 
the factor V Leiden (R506Q) is the most prevalent inherited 
cause of venous thrombosis. The risk of venous thrombosis 
is increased by 3- to 8-fold in the heterozygote form of 
factor V Leiden mutation and 80-fold in the homozygote 
form of factor V Leiden mutation. The prevalence rate of 
factor V Leiden mutation in the general population varies 
by 0% to 15% according to ethnicity.19 It is low in African 
(1%–3%), Asian (1%–3%), south European (2%), and United 
States populations (5%).20 Mediterranean populations harbor 
a relatively high mutant allele with a prevalence of 13.6% in 
Syria, 12.3% in Jordan, and 13.4% in Greece.9,16
Lebanon has one of the highest frequencies of factor 
V Leiden (R506Q) mutation in the eastern Mediterranean 
region and in the world with a prevalence of 14.4% in the 
general population.9 Mutation factor V Leiden was observed 
in 10% of the patients with venous thrombosis and in 64% 
of patients with DVT associated with conditions highly 
suggestive of hypercoagulation. It is considered as the most 
common cause of thrombophilia in these series. 
In a recent publication, Sabbagh and colleagues20 
demonstrated that the prevalence of MTHFR C677T 
polymorphism among the Lebanese population is very high 
(34.6%). With the routine screening of MTHFR C677T 
mutation in Lebanese patients with venous thrombosis, a 
high rate of this mutation has been recorded. It is observed 
in 9.3% of reported patients with DVT and in 43.75% of 
reported patients with DVT and conditions predisposing to 
thrombophilia. It represents the second most frequent cause 
of thrombophilia in this study. MTHFR C677T mutation is an 
independent risk factor for DVT among Chinese and South 
Indian populations.21,22 This mutation was not associated with 
DVT in Turkey and northwestern Greece.23,24 Almawi and 
colleagues25 suggested that factor V Leiden and prothrombin 
G20210A more than MTHFR C677T were important risk 
factors for DVT in the Lebanese population. Further studies 
are required to confirm the importance of MTHFR C677T 
mutation as an inherited risk factor for DVT of lower 
extremities in Lebanese patients.
Prothrombin mutation G20210A is uncommon and 
is found in about 1%–2% in the general population 
worldwide. A similar prevalence has been reported in the 
Lebanese population.26 The relative risk for VTE increases 
2–3-fold for prothrombin G20210A mutation alone and 
20-fold for a combination of prothrombin mutation and 
factor V Leiden mutation.27 We observed heterozygote 
prothrombin G20210A mutation in one of our patients and 
the combination in another patient. Prothrombin mutation 
was detected in 1.23% of the patients with DVT and in 
8% of the patients with DVT and high risk conditions for 
thrombophilia. A recent study compared the contribution 
of factor V Leiden and prothrombin G20210A single 
nucleotide polymorphisms to the genetic susceptibility of 
DVT among Lebanese and Tunisian patients and concluded 
that factor V Leiden mutation is a common risk factor for 
both countries. However, prothrombin G20210A mutation Vascular Health and Risk Management 2009:5 630
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was significantly higher in Lebanese than Tunisians.28 These 
findings illustrate the need to determine prothrombotic gene 
polymorphisms associated with DVT among Mediterranean 
basin communities.
Antiphospholipid antibody syndrome is uncommon. 
It is associated with arterial and venous thrombosis and 
increases 2.5-fold the risk of venous thrombosis.29 Only 
one patient with DVT associated with this syndrome 
was reported in our series. Antiphospholipid antibody 
syndrome can be genetic or acquired. It can vary widely 
in its clinical penetrance depending on the presence of 
triggering factors for VTE such as cancer, the use of 
chemotherapy, or central venous lines which increase the 
thrombotic risk. It has the most adverse outcomes due to 
a high rate of recurrence and high mortality rate if antico-
agulation is discontinued.
Antithrombin III deficiency, protein C and S deficiency 
are very rare and their prevalence in the general population 
does not exceed 0.4%. Reported cases of protein C and S 
deficiency observed in our series were associated with 
heterozygote factor V Leiden mutation.
When acquired risk factors are associated with inherited 
genetic factors, the risk of venous thrombosis is seriously 
increased. This risk becomes prohibitive when homozygote 
forms of mutation is observed or when an association of 
multiple allele mutation is demonstrated.
DVT of lower extremities is very rare before the age of 
20 years and is uncommon in young adults.30 When venous 
thrombosis occurs at a young age, it is often secondary to 
inherited genetic abnormalities. Six of nine patients younger 
than 30 years reported in our series had thrombophilia. 
Congenital inferior vena cava anomalies, either isolated 
or associated to thrombophilia, is a rare cause of DVT in 
young patients but should be always excluded.31–33 In a recent 
study, these congenital anomalies were present in 16.2% of 
young patients with iliac vein thrombosis.34 Although these 
anomalies are rare, however, they represent an important 
risk for venous thrombosis.35,36 When they are associated 
with genetic polymorphism leading to thrombophilia, the 
risk of venous thrombosis can increase several times.37 
Genetic abnormalities associated with inferior vena cava 
anomalies include prothrombin G20210A, factor V Leiden 
(R506Q), MTHFR C677T mutation, and antithrombin III 
deficiency.35–42 We have observed three patients with 
congenital abnormalities of the inferior vena cava (one 
agenesia and two left-sided). The younger patient was 
21 years old. Thrombophilia was detected in two patients 
with these congenital abnormalities.
Bloom and colleagues demonstrated that the overall risk 
of venous thrombosis for cancer was increased 7-fold and 
that this risk was greatly increased with distal metastasis.43 
The risk of venous thrombosis was increased 2-fold in 
cancer patients with factor V Leiden mutation and 2.5-fold 
in cancer patients with prothrombin mutation compared with 
noncarriers.43
The incidence of venous thrombosis increases among 
women using oral contraceptives and increases significantly 
in those women who are also carriers of thrombophilia. 
Administration of oral contraceptives increases the risk 
of venous thrombosis 16-fold in patients heterozygous 
for prothrombin mutation and 20- to 35-fold in patients 
heterozygous for factor V Leiden mutation.44–46 Factor 
V Leiden mutation increases also the risk of venous 
thrombosis in women receiving hormonal therapy.47–48
Pregnant women have an estimated five times increased 
risk of developing venous thrombosis comparing to 
nonpregnant women of similar age.49,50 The risk was highest 
during the third trimester and the first six weeks after 
delivery.50 The prevalence of thrombophilic defects in women 
with venous thrombosis during pregnancy and puerperium 
is very high and varies between 39.5% and 53.5%.51–53 
Pregnant women with inherited thrombophilia have a venous 
thrombosis risk ranging between 3.4 and 15.2.54
Mutation factor V Leiden is the most commonly observed 
inherited genetic factor in pregnant women.54 This mutation, 
essentially in its homozygote form, increases the risk of 
venous thrombosis 34-fold compared to pregnant women 
without the mutation and 52-fold compared to nonpregnant 
women without the mutation.50,55 Prothrombin G20210A 
mutation in pregnant women increases the risk of venous 
thrombosis 31-fold compared to nonpregnant women without 
thrombophilia.50
The evidence of association between prolonged air travel 
and venous thrombosis has not been clearly established. 
However, it seems that the risk of venous thrombosis is 
significant when the flight exceeds 5,000 km or 12 hours 
duration.56 In a recent study, the authors demonstrated that 
prolonged air travel for more than 5,000 km before major 
surgery significantly increases the risk of perioperative 
venous thrombosis.56 Another study has indicated that 72% 
of individuals with travel-related DVT have associated 
coagulation defects.57 These findings illustrate the importance 
of genetic thrombophilic testing in all patients with venous 
thrombosis associated with long-haul air travel.
In this study, 92% of patients with venous thrombosis 
and young age, spontaneous, recurrent, or extensive Vascular Health and Risk Management 2009:5 631
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venous thrombosis, familial history of  VTE, pregnancy, 
estroprogestative treatment, and long-haul air travel 
screened for thrombophilia were positive. Either treated 
with short- or long-term antivitamin K, none of the 
25 patients with vein thrombosis and thrombophilia had 
recurrence or complications related to VTE. Assessment 
of acquired and genetic risk factors for venous thrombosis 
in these patients allowed them to avoid thrombogenic 
treatment (estroprogestative treatment), to prevent venous 
thrombosis in high-risk conditions (pregnancy, surgery, 
and long-haul air travel), and oral anticoagulation could 
be extended for prolonged periods in patients with severe 
thrombophilia or persistent risk factors (cancer, heart 
failure, immobilization, etc.).
A recent study demonstrated that 29% of patients with 
proximal deep vein thrombosis had thrombophilia, which 
is an independent predictor of persistent residual venous 
thrombosis.58 Long-term antivitamin K should be considered 
in patients with more than one episode of recurrent VTE, in 
venous thrombosis with continuous risk factor, in idiopathic 
calf vein thrombosis, and in significant thrombophilia: 
antithrombin III deficiency (homozygote), protein C or S 
deficiency (homozygote), homozygote prothrombin or factor 
V Leiden mutation, and combined heterozygote prothrombin 
and factor V Leiden mutation.
Conclusions
Mutation factor V Leiden (R506Q) (10%), followed by 
MTHFR C677T (9.3%) were the most commonly observed 
inherited genetic abnormalities in this study. Defining risk 
factors and screening for thrombophilia when indicated 
reduced recurrence rate and complications related to VTE. 
Thrombophilia should be screened in:
•  Spontaneous DVT.
•  DVT in young patients (aged less than 50 years).
•  DVT with risk factor of oral contraceptive, estrogen 
replacement therapy, or pregnancy.
•  Familial history of VTE.
•  Extended or recurrent DVT.
•  Recurrent superficial thrombophlebitis without cancer or 
varicose veins.
•  Children with DVT.
•  DVT associated with long-haul air travel.
•  DVT associated with congenital abnormalities of the 
inferior vena cava.
•  Asymptomatic first degree relatives of individuals with 
proven symptomatic thrombophilia. This is particularly 
important for women of child-bearing age.
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